by John R. Fischer
, Senior Reporter | March 20, 2019
An echocardiogram may be one of several essential components necessary for determining if valve repair is likely to help patients suffering from heart failure and a leaking heart valve.
Presented in a new study this past weekend at the American College of Cardiology 68th Annual Scientific Session in New Orleans, the finding builds on the research of the COAPT trial, which explored the use of transcatheter mitral valve repair in patients with secondary mitral regurgitation. Specifically, the focus of the ultrasound component was to depict what the valve looked like and assess the significance of the valvular disease.
“We use ultrasound as an initial way of evaluating any patient or any kind of cardiac condition. It allows us to look at the valves and how the walls in the heart move, and whether there are abnormal structures within the heart,” Dr. Federico Asch, physician and director of Cardiovascular Core Laboratories at MedStar Health Research Institute in Washington, D.C., and one of the authors of the new study, told HCB News. “With the mitral valve in particular, we need to determine not only if the anatomy of the valve and the heart is suitable for an intervention and a device like the MitraClip in this case, but also what the physiology is and how significant the valvular disease is.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Though routinely used to analyze mitral regurgitation, no worldwide standard involving echocardiograms exists for diagnosing secondary mitral regurgitation, limiting its use. By detailing the role of echocardiography, along with other components such as an algorithm used, the study aims to establish such a guideline for clinical decision making, using COAPT as a basis.
The COAPT trial consisted of 614 patients treated at 78 medical centers across the U.S. and Canada who underwent echocardiograms prior to enrollment. Each were either randomly assigned to receive a MitraClip or maximally-tolerated therapy based on clinical guidelines, which can include diuretics, beta blockers, and sometimes, cardiac resynchronization therapy. All had heart failure and moderate-to-severe secondary mitral regurgitation, both of which commonly coexist with one another can worsen a patient’s symptoms.
Researchers utilized echocardiography again at follow-up visits at one, six, 12, 18 and 24 months, deploying a multi-parametric algorithm to interpret heart images, evaluate the function of the valve and determine if patients were appropriate candidates for the MitraClip procedure. The follow-up assessments indicated that the repaired valve prevented backward flow of the blood through the valve, even throughout the two years of follow-up.